IP Library › Granted Patent US 12679889
Granted Patent B2
US 12679889 · App. 18/259,892 · Granted Jul 14, 2026

Oxyntomodulin binding molecules, and uses thereof

Inventors: Robert John Konrad (Carmel, IN); Wenyu Ming (Carmel, IN); Robert William Siegel, II (Fountaintown, IN); Tara Suzanne Umberger (Frankton, IN)
Assignee: Eli Lilly and Company
C07K16/26C12N15/63G01N33/74C07K2317/14C07K2317/565G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679889
App. No.
18/259,892
Granted
Jul 14, 2026
Kind
B2
Abstract

Provided herein are novel N- and C-terminal oxyntomodulin polypeptide binding molecules, and uses thereof, including a method for quantitating oxyntomodulin.

Claims (44)

1 . A polypeptide molecule selected from the group consisting of

(a) a polypeptide molecule that binds the N-terminal region of each of human oxyntomodulin (SEQ ID NO: 25) and human glucagon (SEQ ID NO: 30), wherein the polypeptide molecule comprises the complementarity determining regions (CDRs) set forth in SEQ ID NOS: 1-6 and

(b) a polypeptide molecule that binds the C-terminal region in each of human oxyntomodulin (SEQ ID NO: 25) and human glicentin (SEQ ID NO: 28), wherein the polypeptide molecule comprises the complementarity determining regions (CDRs) set forth in SEQ ID NOS: 13-18.

2 . The polypeptide molecule of claim 1 , wherein the polypeptide molecule is an antibody.

3 . The polypeptide molecule of claim 1 , wherein the polypeptide molecule is an scFv or a Fab.

4 . The polypeptide molecule of claim 1 (a), wherein the polypeptide molecule is an antibody comprising a heavy chain variable region (VH) comprising SEQ ID NO: 7 and a light chain variable region (VL) comprising SEQ ID NO: 8.

5 . The polypeptide molecule of claim 4 , wherein the polypeptide molecule is an antibody comprising a heavy chain comprising SEQ ID NO: 9 and a light chain comprising SEQ ID NO: 10.

6 . The polypeptide molecule of claim 5 , wherein the polypeptide molecule is an antibody comprising a heavy chain consisting of SEQ ID NO: 9 and a light chain consisting of SEQ ID NO: 10.

7 . A nucleic acid molecule selected from the group consisting of

(a) a nucleic acid molecule comprising one or both of a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10 and

(b) a nucleic acid molecule comprising one or both of a first nucleic acid sequence encoding SEQ ID NO: 21 and a second nucleic acid sequence encoding SEQ ID NO: 22.

8 . The nucleic acid molecule of claim 7 (a), wherein the first nucleic acid sequence encoding SEQ ID NO: 9 comprises SEQ ID NO: 11, and wherein the second nucleic acid sequence encoding SEQ ID NO: 10 comprises SEQ ID NO: 12.

9 . A vector selected from the group consisting of

(a) a vector comprising one or both of a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10 and

(b) a vector comprising one or both of a first nucleic acid sequence encoding SEQ ID NO: 21 and a second nucleic acid sequence encoding SEQ ID NO: 22.

10 . A composition comprising the vector of claim 9 .

11 . A cell comprising the vector of claim 9 .

12 . The cell of claim 11 , wherein the cell is a mammalian cell.

13 . A process of producing a polypeptide molecule, comprising culturing a cell comprising

(a) one or both of a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10 or

(b) one or both of a first nucleic acid sequence encoding SEQ ID NO: 21 and a second nucleic acid sequence encoding SEQ ID NO: 22,

under conditions such that the polypeptide molecule is expressed, and recovering the expressed polypeptide molecule from the culture medium.

14 . A polypeptide molecule produced by the process of claim 13 .

15 . A composition comprising the polypeptide molecule of claim 14 .

16 . The polypeptide molecule of claim 1 (b), wherein the polypeptide molecule is an antibody comprising a VH comprising SEQ ID NO: 19 and a VL comprising SEQ ID NO: 20.

17 . The polypeptide molecule of claim 16 , wherein the polypeptide molecule is an antibody comprising a heavy chain comprising SEQ ID NO: 21 and a light chain comprising SEQ ID NO: 22.

18 . The polypeptide molecule of claim 17 , wherein the polypeptide molecule is an antibody comprising a heavy chain consisting of a SEQ ID NO: 21 and a light chain consisting of SEQ ID NO: 22.

19 . The nucleic acid molecule of claim 7 (b), wherein the first nucleic acid sequence encoding SEQ ID NO: 21 comprises SEQ ID NO: 23, and wherein the second nucleic acid sequence encoding SEQ ID NO: 22 comprises SEQ ID NO: 24.

20 . A composition comprising the polypeptide of claim 1 .

21 . A method of determining the concentration of human oxyntomodulin (SEQ ID NO: 25) in a liquid sample, comprising:

(a) contacting a liquid sample comprising human oxyntomodulin with a first polypeptide molecule that binds the C-terminal region in each of human oxyntomodulin (SEQ ID NO: 25) and human glicentin (SEQ ID NO: 28), wherein the first polypeptide molecule comprises the CDRs of SEQ ID NOS: 13-18, thereby forming a first polypeptide molecule-human oxyntomodulin complex;

(b) contacting the first polypeptide molecule-human oxyntomodulin complex with a second polypeptide molecule that binds the N-terminal region of each of human oxyntomodulin (SEQ ID NO: 25) and human glucagon (SEQ ID NO: 30), wherein the second polypeptide molecule comprises the CDRs of SEQ ID NOS: 1-6, thereby forming a first polypeptide molecule-human oxyntomodulin-second polypeptide molecule complex; and

(c) quantitating the amount of oxyntomodulin in the first polypeptide molecule-human oxyntomodulin-second polypeptide molecule complex by comparison against a standard curve of known amounts of human oxyntomodulin (SEQ ID NO: 25).

22 . The method of claim 21 , wherein the liquid sample is serum or plasma.

23 . The method of claim 21 , wherein the first polypeptide molecule is an antibody and the second polypeptide molecule is an antibody.

24 . The method of claim 21 , wherein

the first polypeptide molecule is an antibody comprising a VH comprising SEQ ID NO: 19 and a VL comprising SEQ ID NO: 20, and

the second polypeptide molecule is an antibody comprising a VH comprising SEQ ID NO: 7 and a VL comprising SEQ ID NO: 8.

25 . The method of claim 21 , wherein

the first polypeptide molecule is an antibody comprising a heavy chain comprising SEQ ID NO: 21 and comprising a light chain comprising SEQ ID NO: 22, and

the second polypeptide molecule is an antibody comprising a heavy chain comprising SEQ ID NO: 9 and a light chain comprising SEQ ID NO: 10.

26 . The method of claim 21 , wherein

the first polypeptide molecule is an antibody comprising a heavy chain consisting of SEQ ID NO: 21 and a light chain consisting of SEQ ID NO: 22, and

the second polypeptide molecule is an antibody comprising a heavy chain consisting of SEQ ID NO: 9 and a light chain consisting of SEQ ID NO: 10.